Dynamic Advisor Solutions LLC Sells 1,013 Shares of Sanofi (NASDAQ:SNY)

Dynamic Advisor Solutions LLC decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 1.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,831 shares of the company’s stock after selling 1,013 shares during the period. Dynamic Advisor Solutions LLC’s holdings in Sanofi were worth $3,218,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of SNY. Connectus Wealth LLC bought a new stake in shares of Sanofi during the 4th quarter valued at about $828,000. Strategic Global Advisors LLC boosted its position in Sanofi by 25.6% during the 4th quarter. Strategic Global Advisors LLC now owns 7,345 shares of the company’s stock valued at $365,000 after acquiring an additional 1,496 shares in the last quarter. Putnam Investments LLC grew its holdings in shares of Sanofi by 25.9% during the 4th quarter. Putnam Investments LLC now owns 1,342,709 shares of the company’s stock worth $66,773,000 after acquiring an additional 276,259 shares during the period. Garner Asset Management Corp bought a new position in shares of Sanofi in the 4th quarter worth approximately $97,000. Finally, True Wealth Design LLC lifted its stake in shares of Sanofi by 13.2% in the 4th quarter. True Wealth Design LLC now owns 15,651 shares of the company’s stock valued at $778,000 after purchasing an additional 1,823 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Stock Up 0.2 %

Shares of NASDAQ:SNY opened at $54.85 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a fifty day simple moving average of $55.58 and a two-hundred day simple moving average of $51.19. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The stock has a market capitalization of $138.92 billion, a price-to-earnings ratio of 27.56, a PEG ratio of 1.58 and a beta of 0.60.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The firm had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. During the same quarter in the previous year, the firm earned $0.95 EPS. Sanofi’s quarterly revenue was up 7.8% compared to the same quarter last year. On average, research analysts anticipate that Sanofi will post 4.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.